Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill addresses federal support and research for bleeding disorder patients and treatment.
The problem
Bleeding disorders affect thousands of Americans. Patients need better access to treatment, research funding, and coordinated federal health programs.
The proposal
The bill likely increases federal funding for bleeding disorder research, improves patient access programs, and coordinates efforts across federal health agencies.
The impact
Patients with bleeding disorders, their families, healthcare providers, and medical researchers benefit from increased support and resources.
Increased federal investment in bleeding disorder research could lead to new treatments and cures. This helps scientists develop better medicines faster. Patients get access to improved care options.
Federal support programs help patients afford treatments and medications. This reduces financial burden on families struggling with expensive bleeding disorder care. More people can get the help they need.
Bringing together different federal agencies creates better planning and response. Healthcare providers get clearer guidelines. Patients experience more consistent, organized support across programs.
Federal programs increase education about bleeding disorders. Doctors diagnose conditions faster. The public learns about treatment options available to them.
New spending requires taxpayer funding. The bill creates ongoing federal expenses. Congress must decide how to pay for these programs without cutting other areas.
Without seeing the actual bill text, unclear how programs will work. Poorly designed initiatives might waste money. Coordination between agencies can be complicated and slow.
New federal programs add government agencies and paperwork. Patients may face delays accessing services. Administrative costs could reduce money going directly to care.
Federal programs might compete with private insurance and pharmaceutical companies. This could reduce market competition. Companies may have less incentive to develop new treatments independently.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.